ADGI Adagio Therapeutics Inc.

51.46
-4.62  -8%
Previous Close 56.08
Open 56.02
52 Week Low 20.5
52 Week High 59.5
Market Cap $5,724,701,664
Shares 111,245,660
Float 64,011,030
Enterprise Value $6,316,957,612
Volume 3,804,890
Av. Daily Volume 492,832
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
ADG20 (STAMP)
COVID-19 (treatment)
Phase 2/3
Phase 2/3
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
ADG20 (EVADE)
COVID-19 (prevention)
Phase 2/3
Phase 2/3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Latest News

  1. WALTHAM, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (NASDAQ:ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced that Tillman Gerngross, Ph.D., co-founder and chief executive officer of Adagio, will participate in a fireside chat during the Morgan Stanley 19th Annual Global Healthcare Conference on Wednesday, Sept. 15, 2021 at 1:15 p.m. ET.

    The live webcast will be available in the investor section of the company's website at www.investors.adagiotx.com. The webcast will be archived for 60 days following the presentation.

    About Adagio Therapeutics
    Adagio (NASDAQ…

    WALTHAM, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (NASDAQ:ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced that Tillman Gerngross, Ph.D., co-founder and chief executive officer of Adagio, will participate in a fireside chat during the Morgan Stanley 19th Annual Global Healthcare Conference on Wednesday, Sept. 15, 2021 at 1:15 p.m. ET.

    The live webcast will be available in the investor section of the company's website at www.investors.adagiotx.com. The webcast will be archived for 60 days following the presentation.

    About Adagio Therapeutics

    Adagio (NASDAQ:ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company's portfolio of antibodies has been optimized using Adimab's industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio's portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch. For more information, please visit www.adagiotx.com.

    Contacts:

    Media Contact:

    Dan Budwick, 1AB

    Dan@1abmedia.com 

    Investor Contact:

    Monique Allaire, THRUST Strategic Communications

    monique@thrustsc.com 



    Primary Logo

    View Full Article Hide Full Article
View All Adagio Therapeutics Inc. News